Kiniksa Pharmaceuticals International (KNSA) Total Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Total Liabilities for 10 years, with the latest figure at $219.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 54.82% year-over-year to $219.6 million; the trailing twelve-month figure through Mar 2026 stood at $219.6 million (up 54.82% YoY), and the FY2025 full-year result was $196.0 million, up 37.93% from the prior year.
• Total Liabilities for Q1 2026 stood at $219.6 million, up from $196.0 million in the prior quarter.
• The five-year high for Total Liabilities was $219.6 million in Q1 2026, with the low at $52.8 million in Q1 2023.
• Historically, Total Liabilities has averaged $112.2 million across 5 years, with a median of $87.8 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 95.68% — and 2023, when it slipped 18.47%.
• Kiniksa Pharmaceuticals International's Total Liabilities stood at $63.5 million in 2022, then jumped by 37.72% to $87.5 million in 2023, then soared by 62.45% to $142.1 million in 2024, then soared by 37.93% to $196.0 million in 2025, then increased by 12.02% to $219.6 million in 2026.
• The last three Total Liabilities figures came in at $219.6 million (Q1 2026), $196.0 million (Q4 2025), and $177.0 million (Q3 2025), per Business Quant data.